Retatrutide Could Change Everything… But Who Actually Gets It?

ON THE PEN RESOURCES AND LINKS: HTTPS://WWW.OTPLINKS.COM

What if the most powerful obesity drug ever created ends up being the one you can’t get?

That’s the real conversation around retatrutide right now.

In this video, I break down what Eli Lilly is doing behind the scenes, and why this isn’t just about whether retatrutide is better than tirzepatide. This is about strategy. This is about access. And this is about who gets left behind.

We’re talking about:
• The push to classify retatrutide as a biologic
• Why that could mean pricing in the $7,000/month range
• How LillyDirect is changing access to tirzepatide
• The “two lane” system that could define obesity treatment going forward
• And what this means for patients already struggling to stay on GLP-1 therapies

If you’ve ever fought insurance, dealt with compounding disappearing, or felt like the system decides what you’re allowed to have… this one is for you.

👇 Let’s talk about it
Have you ever felt stuck between “this is working” and “this isn’t enough”… with no clear path forward?

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(197)

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...

23 Kesä 44min

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ⁠ to break down the molecules, clinica...

16 Kesä 1h 15min

Retatrutide Just Reached Bariatric Surgery Results

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference....

11 Kesä 48min

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

9 Kesä 20min

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Kesä 20min